Novartis AG (NVS) — Q2 FY26 Earnings Call Live coverage with Benzinga. Q2 FY26 Results EPS: $2.41 (est. $2.16) — inline Revenue: $14.41B (est. $14.12B) — inline Reported: 2026-07-21 Recent Quarters Q1 FY26 (2026-04-28): EPS $1.99 vs est $2.07 · Rev $13.11B vs est $13.50B Q4 FY25 (2026-02-04): EPS $2.03 vs est $2.00 · Rev $13.34B vs est $13.93B Q3 FY25 (2025-10-28): EPS $2.25 vs est $2.29 · Rev $13.91B vs est $13.87B Q2 FY25 (2025-07-17): EPS $2.47 vs est $2.38 · Rev $14.05B vs est $14.06B About Novartis AG Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue. novartis.com · Basel, CHE · 75,267 employees Follow Benzinga X: x.com/Benzinga Faceboo...